Compounds > phosphorus
Page last updated: 2024-09-04

phosphorus and 2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3

phosphorus has been researched along with 2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3 in 1 studies

Compound Research Comparison

Studies
(phosphorus)		Trials
(phosphorus)		Recent Studies (post-2010)
(phosphorus)		Studies
(2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3)		Trials
(2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3)		Recent Studies (post-2010) (2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3)
48,0741,12617,1391238

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blaser, WJ; Buck, RD; Clagett-Dame, M; DeLuca, HF; Knutson, DC; Plum, LA; Thadhani, R; Zella, JB1

Trials

1 trial(s) available for phosphorus and 2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3

ArticleYear
2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial.
    American journal of nephrology, 2017, Volume: 45, Issue:1

    Topics: Adult; Aged; Calcitriol; Calcium; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome

2017